The identified small-molecule binders would serve as starting points for the development of high-affinity binders of the LRRK2 WD40 domain that may be potent inhibitors of LRRK2 in cells and could be further developed as therapeutics for PD. The gene discussed is LRRK2; the disease is Parkinson disease.